HYL — Hyloris Pharmaceuticals SA Share News
0.000.00%
Last trade - 00:00- €108.08m
- €100.44m
- €7.21m
Brief: Hyloris Announces FDA Approval Of Maxigesic IV
Hyloris Pharma wins US FDA approval for pain treatment
Brief: Hyloris Pharmaceuticals Says During H1 2023, Total Revenue, Other Income Increased To EUR 2,391 Thousand Versus EUR 1,229 Thousand In H1 2022
Brief: Hyloris: Enrolment Of First Patient In 4-Arm Clinical Trial Of Alenura
Brief: Hyloris Pharmaceuticals Receives EUR 1 Mln In Non-Dilutive Funding From Walloon Region
Brief: Hyloris Announces Potential US Maxigesic Registration Date
Brief: Hyloris Submits Maxigesic IV Packaging Data Requested By FDA
Hyloris présente ses résultats annuels pour 2022 et ses perspectives d’avenir
Hyloris reports full year results for 2022 & provides business outlook
Brief: Hyloris: Commercial Partnership For Maxigesic® ® IV In 9 European Countries
Brief: Hyloris Pharmaceuticals Expands Pipeline With Product Candidate For Hypophosphatemia
Brief: Hyloris Pharmaceuticals Broadens Pipeline With Nasal Product Candidate For Idiopathic Rhinitis
Brief: Hyloris Pharmaceuticals H1 Total Revenue Up At EUR 1.23 Mln
Brief: Hyloris Reports Positive Phase 1 Data For HY-004
Brief: Hyloris Says FDA Requests Additional Data For Maxigesic IV
Brief: Bookrunner Says Hyloris Pharmaceuticals ABB Priced At EUR 15.50 Per Share
Brief: Hyloris Successfully Raises EUR 15.0 Mln In An Equity Offering
Brief: Hyloris Pharmaceuticals NV ABB Bookrunner Says Books Are Closed
Brief: Hyloris Pharmaceuticals NV ABB Bookrunner Says Orders Below EUR 15.50 Risk Missing